Effects of Vegetable Proteins on Hypercholesterolemia and Gut Microbiota Modulation
- PMID: 30200592
- PMCID: PMC6164761
- DOI: 10.3390/nu10091249
Effects of Vegetable Proteins on Hypercholesterolemia and Gut Microbiota Modulation
Abstract
Risk assessment tools, i.e., validated risk prediction algorithms, to estimate the patient's 10-year risk of developing cardiovascular disease (CVD) should be used to identify high-risk people for primary prevention. Current evidence confirms that appropriate monitoring and control of risk factors either reduces the likelihood of CVD or slows down its progression. It is thus crucial that all health professionals make appropriate use of all the available intervention strategies to control risk factors: from dietary improvement and adequate physical activity to the use of functional foods, food supplements, and drugs. The gut microbiota, which encompasses 1 × 1014 resident microorganisms, has been recently recognized as a contributing factor in the development of human disease. This review examines the effect of both some vegetable food components belong to the "protein food group" and the underexploited protein-rich hempseed on cholesterolemia and gut microbiota composition.
Keywords: LDL-receptor; PCSK9; cholesterol; functional food; hempseed; lupins; microbiota; peas; protein food group; soybeans.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


References
-
- Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M.T., Corra U., Cosyns B., Deaton C., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur. Heart J. 2016;37:2315–2381. doi: 10.1093/eurheartj/ehw106. - DOI - PMC - PubMed
-
- Goff D.C., Jr., Lloyd-Jones D.M., Bennett G., Coady S., D’Agostino R.B., Sr., Gibbons R., Greenland P., Lackland D.T., Levy D., O’Donnell C.J., et al. American College of Cardiology/American Heart Association Task Force on Practice, G., 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC. 2014;63:2935–2959. doi: 10.1016/j.jacc.2013.11.005. - DOI - PMC - PubMed
-
- Jaspers N.E.M., Visseren F.L.J., Numans M.E., Smulders Y.M., van Loenen Martinet F.A., van der Graaf Y., Dorresteijn J.A.N. Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: A cross-sectional study of patient and primary care physician perspectives. BMJ Open. 2018;8:e021309. doi: 10.1136/bmjopen-2017-021309. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous